New Gene Therapy at a World-Renowned Research Insitute
07 August 2019
There is a new NF2 Gene Therapy Pilot Pre-Clinical Study at the Abigail Wexner Research Institute at Nationwide Children’s Hospital (NCH) by Dr. Kathrin Meyer, who is serving as the Principal Investigator.
This lab is considered to be one of the top gene therapy labs in the world, therefore NF2 patients and families can be assured that the best gene therapy researchers are working on curing NF2, but NF2 Biosolutions needs your support to help fund these projects.
Dr. Meyer will be the principal investigator for this NF2 project. Dr Meyer focuses on studying disease mechanisms in neurodegenerative diseases and finding new innovative therapeutic strategies for them. A main emphasis is understanding the impact of different mutations on disease course and severity. Moreover, Dr. Meyer’s lab has a strong translational focus in her projects with the goal to move additional programs towards clinical trials. These projects include the optimization of delivery strategies and evaluation of efficacy and targeting of various areas of the nervous system with gene therapy.
Dr. Kathrin Meyer
Investigators at the Center for Gene Therapy in The Research Institute at Nationwide Children’s Hospital are currently conducting numerous clinical research studies on other diseases like Batten, Charcot-Marie-Tooth Neuropathy Type 1, Duchenne Muscular Dystrophy, Mucopolysaccharidosis (MPS). See the list here.
The recently FDA approved gene therapy for treatment of the fatal genetic disorder SMA was developed at Nationwide Children’s Hospital. This approval was groundbreaking and is the first and only systemically administered gene therapy approved by the FDA in the US.
Read more about how NCH became ground zero for gene therapy by clicking on the link below:
This is also a therapy that NF2 Biosolutions are strongly endorsing, we would strongly encourage you to visit their website by clicking on the link below:
Filter News
Eashan’s NF1 story
'Why Run'... Eashan was diagnosed with NF1 after losing his eyesight when he was 5. His mother Jen tells his story.
Read More2023 Awareness Campaign
Nerve Tumours UK have joined forces with RBH to raise awareness for a second successive year.
Read MoreDisclosing and explaining visible differences - CAR Workshop
Read more about the workshop, featuring additional guidance from Specialist NF Nurse Rebecca Rennison
Read MoreJo Ward’s Avastin Blog
Jo Ward, CEO of NF2 BioSolutions UK, shares a blog about her son Oscar's Avastin journey
Read MoreNigel’s story - Normal is as normal does
Nigel lived a normal life until age 47. The next 20 years took him from NF1 to NF2 to Schwannomatosis to mosaic NF2
Read MoreWorld Mental Health Day 2023
NTUK (as part of the Neurological Alliance) has signed a joint letter aimed at improving access to mental health services
Read MoreCAR Research visible difference experiences during recruitment
Research participants required, find out more and take part
Read MoreNF Academy 2023 - Ella’s Blog
Ella, who has NF1, attended the week-long 2023 NF Academy in Portugal, meeting young adults with NF from all over Europe
Read MoreUniversity of Manchester Research
Read about the latest PHD research, involving Nerve Tumours UK, at the University of Manchester
Read More